Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) study.

[Display omitted] • Contemporary epidemiology and outcomes of AMI in France. • Identification of emerging risk factors and new prognostic determinants of AMI. • Long-term follow-up by automated link with the French national health database. • Healthcare consumption and medico-economic impact of myocardial infarction. • Platform for cohort-nested studies, both observational and randomized. Despite major advances in prevention and treatment, cardiovascular diseases – particularly acute myocardial infarction – remain a leading cause of death worldwide and in France. Collecting contemporary data about the characteristics, management and outcomes of patients with acute myocardial infarction in France is important. The main objectives are to describe baseline characteristics, contemporary management, in-hospital and long-term outcomes of patients with acute myocardial infarction hospitalized in tertiary care centres in France; secondary objectives are to investigate determinants of prognosis (including periodontal disease and sleep-disordered breathing), to identify gaps between evidence-based recommendations and management and to assess medical care costs for the index hospitalization and during the follow-up period. FRENCHIE (FRENch CoHort of myocardial Infarction Evaluation) is an ongoing prospective multicentre observational study (ClinicalTrials.gov Identifier: NCT04050956) enrolling more than 19,000 patients hospitalized for acute myocardial infarction with onset of symptoms within 48 hours in 35 participating centres in France since March 2019. Main exclusion criteria are age < 18 years, lack of health coverage and procedure-related myocardial infarction (types 4a and 5). Detailed information was collected prospectively, starting at admission, including demographic data, risk factors, medical history and treatments, initial management, with prehospital care pathways and medication doses, and outcomes until hospital discharge. The follow-up period (up to 20 years for each patient) is ensured by linking with the French national health database (Système national des données de santé), and includes information on death, hospital admissions, major clinical events, healthcare consumption (including drug reimbursement) and total healthcare costs. FRENCHIE is also used as a platform for cohort-nested studies – currently three randomized trials and two observational studies. This nationwide large contemporary cohort with very long-term follow-up will improve knowledge about acute myocardial infarction management and outcomes in France, and provide a useful platform for nested studies and trials. [ABSTRACT FROM AUTHOR]